A single-dose study of denosumab in patients with various degrees of renal impairment. - Wikidata - awgldk - TriplyDB

A single-dose study of denosumab in patients with various degrees of renal impairment.

A single-dose study of denosumab in patients with various degrees of renal impairment.

http://www.wikidata.org/entity/Q36420481

about

A review of denosumab for the treatment of osteoporosis Denosumab for the treatment of osteoporosis New antiresorptive therapies for postmenopausal osteoporosis Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer Chronic kidney disease and osteoporosis: evaluation and management.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer Side effects of bone-targeted therapies in advanced breast cancer.Treatment of immobilization-related hypercalcaemia with denosumab.Prolonged hypocalcaemia following a single dose of 60 mg denosumab in two patients with CKD 4/5 on cinacalcet treatment for tertiary hyperparathyroidism.Chronic kidney disease and the skeleton.Management of severe osteoporosis.Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer Specific method validation and sample analysis approaches for biocomparability studies of denosumab addressing method and manufacture site changes Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.Bisphosphonates for Osteoporosis in Patients with Renal Insufficiency: Pharmacists' Practices and Beliefs.Impact of denosumab on bone mass in cancer patients.Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease.Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.The Strategy to Prevent and Regress the Vascular Calcification in Dialysis Patients.Osteoporosis in men: epidemiology and treatment with denosumab.Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions.Therapy for patients with CKD and low bone mineral density.Denosumab in osteoporosis.The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.Managing bone metastases and reducing skeletal related events in prostate cancer.Biological agents in management of osteoporosis.Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.Considerations regarding adherence of anti-osteoporosis therapy.Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.How to predict and treat increased fracture risk in chronic kidney disease.Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing.Bone Disorders in Chronic Kidney Disease: An Update in Diagnosis and Management.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients.Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.

P2860

Q27005894-54047400-DAF3-4058-8AB2-B5A594872683 Q27009275-5E9CBA05-8A34-45D3-8480-C7BAA88165E6 Q27014775-24F51356-F512-4506-8CF3-14E760B2A32A Q28076646-B4DCB2BF-E61E-49D8-86A7-4E8C9A831555 Q28087676-7DA14EB4-97E4-4C56-9ADB-FB28F0BC049F Q30234751-C65A16E1-F959-4C90-A091-922B73E1F84B Q33611876-75600CC4-80FE-42F6-9770-F1CAE1FEF3B0 Q33833414-002C240E-47F9-44F4-A202-186BD5726B21 Q34023510-793A8BF6-D4D6-4C21-A4E1-AA5CDB701DF8 Q35066955-690E86C3-A406-4157-9DB8-C3D7B64594C0 Q35453039-E2A214CC-73C8-4113-9248-DD51BE8EDB6E Q35608481-D1A1E7DE-C8A1-4E4B-967F-1BFEC7463DD1 Q35755179-BD5B23D4-49EF-44BD-9300-47224F308279 Q35852252-A7A13D27-8C1F-43C8-A040-5DEE04A9DEE2 Q36345986-6EEE196D-7ED5-4D61-A515-47E09AC054F9 Q36502429-2B10E49A-CE32-4155-B80E-265621666465 Q36553506-769E45EA-E346-42C7-9312-133243F381C4 Q36649495-CD9B5B96-DF29-42CD-A8AD-B5FC3F5F966B Q37000157-BEC2E5FF-1545-48BE-B092-2D1E2CE5A741 Q37327059-62D41111-B438-4A14-AF6B-4C0309F040A9 Q37443111-55D23FCB-4892-4114-AB74-576DB1218695 Q37488814-0512EADE-7A2D-4EFB-9395-59131204EA2C Q37670856-37818E16-FAB6-486B-8770-C3FE659DA933 Q37702188-F6891ABF-BEB4-482C-92A2-5440967B6FE6 Q38144897-F6C61CB0-6457-4F93-9C81-783F7425324C Q38150099-C000FC26-96D6-4F03-AE01-EFA333115E1F Q38167352-1C60ED5C-83B4-4088-AF29-48DC5990852C Q38193181-702EB417-32F5-4D67-BADE-25E8DB64C2B1 Q38211359-4B446257-9571-41CF-99E3-4824CD175A6C Q38247465-73E935DB-EE33-4901-845C-432A3EA741D5 Q38271045-87246A88-62FB-4F50-A408-9A1CE2E8CCA9 Q38294766-2A0EE4B2-ED27-4451-85B6-D726AF53C84E Q38364467-1CEA9CC2-B704-4C32-B0C2-091E7B3B01F9 Q38372851-1CFE47FD-75B2-4113-83C7-357C4F9FD4F3 Q38571774-F4FA1A0E-9CBE-4F8C-ACC0-E5B48CA4A575 Q38579166-E157BEA2-16B4-4E53-A467-BE57E24AD7C7 Q38712724-C84E84A3-A654-44C7-AC67-C349CA35009E Q38733725-C67FDD22-E426-49E9-9003-170037B135CE Q38978628-D52CE30C-2A30-4868-9B6F-FD927C9046AF Q38984955-42FF1892-B4E8-4285-A29E-05F8D412C0D4

P2860

A single-dose study of denosumab in patients with various degrees of renal impairment.

http://www.wikidata.org/entity/Q36420481

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

A single-dose study of denosumab in patients with various degrees of renal impairment.

@ast

A single-dose study of denosumab in patients with various degrees of renal impairment.

@en

type

label

A single-dose study of denosumab in patients with various degrees of renal impairment.

@ast

A single-dose study of denosumab in patients with various degrees of renal impairment.

@en

prefLabel

A single-dose study of denosumab in patients with various degrees of renal impairment.

@ast

A single-dose study of denosumab in patients with various degrees of renal impairment.

@en

P1433

Q36420481-E2B68254-0455-48C8-8C66-C0DC2A529581

P1476

Q36420481-0776371D-ABB5-45D5-9F08-1F8379497366

P2093

Q36420481-263823E3-9D6F-41D1-929E-212A9B1F7FC8

Q36420481-37EDE173-056D-4044-A0AF-2ECB1DC6855A

Q36420481-6D7A287E-AAD8-46D0-8CF8-D53506DDD516

Q36420481-A354F55C-01A4-4FC2-84BB-A27F213B9417

Q36420481-D3FD6763-E2D2-4A6A-8918-1121C0E22A55

P2860

Q36420481-05010B52-040B-4F56-A2C8-6E87DD3E6D8F

Q36420481-16336DC2-26AC-4E11-85BE-8DED3E1FD2DD

Q36420481-27713F4C-2384-4214-9246-788DB243D2D6

Q36420481-3232B59C-C2C0-4447-90FE-2E3C256AF1B1

Q36420481-39D62669-3042-4171-AC8F-DAF352039AC5

Q36420481-3B522025-D967-4E36-B324-428963535056

Q36420481-443BFEDD-5E50-4FD6-BB9C-2246803282E7

Q36420481-4941A860-B5DF-4755-837A-7D78F6936F76

Q36420481-63C97A73-C8EC-4959-A4F5-7AB4A61036A6

Q36420481-6D0F4D3B-B019-4AA2-A823-9734E42504AE

P304

Q36420481-D4A842B7-E933-4435-A887-E4AF78653BFE

P31

Q36420481-CC9BDA88-71C7-418C-B2B3-4F9243130A78

P356

Q36420481-AE38DE1C-0C32-400C-A9B8-C8D313B51090

P433

Q36420481-B0B359B9-F80E-4EFC-BACA-5C3D4A821379

P478

Q36420481-8A45542E-6737-4225-8CB1-C0B9828E3900

P577

Q36420481-CAB99FA5-C808-47C7-A780-497666B6172D

P5875

Q36420481-24032678-13A2-4994-AA31-27313BC663A0

P698

Q36420481-BD0E6451-14C4-47F9-AED5-A692B0690C2A

P932

Q36420481-0F0C3897-5BC0-404D-A1DC-77B413734919

P356

P1433

Journal of Bone and Mineral Research

P1476

A single-dose study of denosumab in patients with various degrees of renal impairment.

@en

P2093

Desmond Padhi

http://www.w3.org/2001/XMLSchema#string

Edward Lee

http://www.w3.org/2001/XMLSchema#string

Geoffrey A Block

http://www.w3.org/2001/XMLSchema#string

Henry G Bone

http://www.w3.org/2001/XMLSchema#string

Liang Fang

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Denosumab in postmenopausal women with low bone mineral density

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Prediction of creatinine clearance from serum creatinine

The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.

Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study.

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

Bisphosphonate nephrotoxicity.

P304

1471-1479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.1613

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223989786

http://www.w3.org/2001/XMLSchema#string

P698

22461041

http://www.w3.org/2001/XMLSchema#string

P932

3505375

http://www.w3.org/2001/XMLSchema#string